Sacituzumab Govitecan (IMMU-132) in treatment-resistant uterine serous carcinoma: A case report

Uterine serous carcinoma (USC) is a biologically aggressive variant of uterine cancer. Effective treatment options for recurrent, chemotherapy-resistant USC are extremely limited. We describe a 74-year-old woman with recurrent and widespread treatment-resistant disease, who experienced a dramatic response to sacituzumab govitecan, a novel antibody-drug conjugate (ADC) targeting human trophoblast-cell-surface antigen (TROP-2), after failing multiple chemotherapy and immunotherapy. The impressive clinical response (66% reduction of target lesions by RECIST 1.1 with a duration response of over 10 months) was confirmed with serial CT scans in the absence of significant adverse events. Sacituzumab govitecan may present a new treatment option for recurrent USC patients harboring Trop-2+ tumors resistant to chemotherapy. Clinical trials with sacituzumab govitecan are warranted. •Uterine serous carcinoma (USC) is a rare but aggressive variant of uterine cancer.•Sacituzumab-govitecan (IMMU-132) is an antibody-drug conjugate targeting TROP-2.•IMMU-132 may represent a new treatment option for USC overexpressing TROP-2.